RxDoctor Payments Data

Brooke Hills

Family · Wahpeton, NDNPI 1144662719

Payments from drug & device makers

$372in general payments, 2019–2025

Across 24 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$84
  • Astellas Pharma US Inc$44
  • Sanofi-aventis U.S. LLC$27
  • Phathom Pharmaceuticals, Inc.$24
  • AstraZeneca$23
  • GSK$21
  • plus $149 from 10 others

What the payments were for

  • Food & beverage$372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$372 in reported general payments places this provider in the 65th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$61,888
Medicare patients
211
Services billed
5,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$72,803
OzempicSemaglutide50$62,412
Soliqua 100-33Insulin Glargine/Lixisenatide57$49,273
JardianceEmpagliflozin24$27,435
FarxigaDapagliflozin Propanediol24$20,707
JanuviaSitagliptin Phosphate23$19,298
XareltoRivaroxaban13$11,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,655
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,616
Breo ElliptaFluticasone/Vilanterol12$6,251
Atorvastatin Calcium307$2,725
Metoprolol Succinate144$2,251
Levothyroxine Sodium189$1,915
Bupropion XlBupropion Hcl50$1,743
Losartan Potassium175$1,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$62,41250 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$27$49,27357 claims
AstraZenecaFarxiga, Breztri Aerosphere$23$28,32236 claims
Boehringer IngelheimJardiance$13$27,43524 claims
GSKTrelegy Ellipta, Breo Ellipta$21$15,90627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 496 family providers in North Dakota.

Other family in Wahpeton

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →